Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients ...

Additionally, FPT’s digital transformation solution for Long Chau Pharmacy has enhanced the customer experience by enabling ...

Ho Chi Minh City plans to pilot mechanisms for pharmaceutical companies to adopt digital technologies, showcasing its ...

CAG reported handling a total of 1.99 million tonnes of airfreight in 2024, up 14.6 per cent from 2023. Read more at straitstimes.com.

A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...

This Phase 1b/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA ® ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your email, you agree to the Privacy ...